Mobile

A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib at 6 mg/kg/day versus placebo in pat...

Mise à jour : Il y a 4 ans
Référence : EUCTR2010-021495-29

A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib at 6 mg/kg/day versus placebo in patients with severe Chronic Obstructive Pulmonary Disease (COPD)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The objective is to compare the efficacy and the safety of masitinib at 6 mg/kg/day versus placebo in the treatment of patients with severe COPD. Primary endpoint: • Absolute change from randomisation in the 6-minutes walking distance test at Week 24

Critère d'inclusion

  • Severe Chronic Obstructive Pulmonary Disease (COPD)

Liens